194 related articles for article (PubMed ID: 10878487)
1. Humoral and cellular autoimmunity in autoimmune bullous skin disorders.
Hertl M
Int Arch Allergy Immunol; 2000 Jun; 122(2):91-100. PubMed ID: 10878487
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the T cells that are potentially involved in autoantibody production in pemphigus vulgaris.
Hertl M; Riechers R
J Dermatol; 1999 Nov; 26(11):748-52. PubMed ID: 10635617
[TBL] [Abstract][Full Text] [Related]
3. The desmosome and hemidesmosome in cutaneous autoimmunity.
Lin MS; Mascaró JM; Liu Z; España A; Diaz LA
Clin Exp Immunol; 1997 Jan; 107 Suppl 1():9-15. PubMed ID: 9020929
[TBL] [Abstract][Full Text] [Related]
4. Frequency analysis of autoreactive T-helper 1 and 2 cells in bullous pemphigoid and pemphigus vulgaris by enzyme-linked immunospot assay.
Eming R; Büdinger L; Riechers R; Christensen O; Bohlen H; Kalish R; Hertl M
Br J Dermatol; 2000 Dec; 143(6):1279-82. PubMed ID: 11122034
[TBL] [Abstract][Full Text] [Related]
5. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles.
Veldman C; Stauber A; Wassmuth R; Uter W; Schuler G; Hertl M
J Immunol; 2003 Jan; 170(1):635-42. PubMed ID: 12496453
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells.
Eming R; Hennerici T; Bäcklund J; Feliciani C; Visconti KC; Willenborg S; Wohde J; Holmdahl R; Sønderstrup G; Hertl M
J Immunol; 2014 Nov; 193(9):4391-9. PubMed ID: 25252957
[TBL] [Abstract][Full Text] [Related]
7. T-cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin.
Hertl M; Veldman C
Autoimmun Rev; 2003 Sep; 2(5):278-83. PubMed ID: 12965179
[TBL] [Abstract][Full Text] [Related]
8. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
Atzori L; Deidda S; Aste N
G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
[TBL] [Abstract][Full Text] [Related]
9. Induction of T regulatory cells by the superagonistic anti-CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA-transgenic mouse model of pemphigus vulgaris.
Schmidt T; Willenborg S; Hünig T; Deeg CA; Sonderstrup G; Hertl M; Eming R
Exp Dermatol; 2016 Apr; 25(4):293-8. PubMed ID: 26661498
[TBL] [Abstract][Full Text] [Related]
10. [Autoimmune bullous skin diseases].
Joly P
Rev Med Interne; 1999 Jan; 20(1):26-38. PubMed ID: 10220817
[TBL] [Abstract][Full Text] [Related]
11. Skin-infiltrating T cells display distinct inflammatory signatures in lichen planus, bullous pemphigoid and pemphigus vulgaris.
Schinner J; Cunha T; Mayer JU; Hörster S; Kind P; Didona D; Keber C; Hertl M; Worzfeld T; Juratli HA
Front Immunol; 2023; 14():1203776. PubMed ID: 37415985
[TBL] [Abstract][Full Text] [Related]
12. The role of T cells in pemphigus vulgaris and bullous pemphigoid.
Fang H; Li Q; Wang G
Autoimmun Rev; 2020 Nov; 19(11):102661. PubMed ID: 32942041
[TBL] [Abstract][Full Text] [Related]
13. T cell control in autoimmune bullous skin disorders.
Hertl M; Eming R; Veldman C
J Clin Invest; 2006 May; 116(5):1159-66. PubMed ID: 16670756
[TBL] [Abstract][Full Text] [Related]
14. Type 2 T-Cell Responses against Distinct Epitopes of the Desmoglein 3 Ectodomain in Pemphigus Vulgaris.
Didona D; Scarsella L; Hudemann C; Volkmann K; Zimmer CL; Beckert B; Tikkanen R; Korff V; Kühn K; Wienzek-Lischka S; Bein G; Di Zenzo G; Böhme J; Cunha T; Solimani F; Pieper J; Juratli HA; Göbel M; Schmidt T; Borradori L; Yazdi AS; Sitaru C; Garn H; Eming R; Fleischer S; Hertl M
J Invest Dermatol; 2024 Feb; 144(2):263-272.e8. PubMed ID: 37717934
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls.
Büdinger L; Borradori L; Yee C; Eming R; Ferencik S; Grosse-Wilde H; Merk HF; Yancey K; Hertl M
J Clin Invest; 1998 Dec; 102(12):2082-9. PubMed ID: 9854043
[TBL] [Abstract][Full Text] [Related]
16. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris.
Lin MS; Swartz SJ; Lopez A; Ding X; Fernandez-Vina MA; Stastny P; Fairley JA; Diaz LA
J Clin Invest; 1997 Jan; 99(1):31-40. PubMed ID: 9011573
[TBL] [Abstract][Full Text] [Related]
17. Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals.
Hertl M; Amagai M; Sundaram H; Stanley J; Ishii K; Katz SI
J Invest Dermatol; 1998 Jan; 110(1):62-6. PubMed ID: 9424089
[TBL] [Abstract][Full Text] [Related]
18. Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3.
Nagel A; Lang A; Engel D; Podstawa E; Hunzelmann N; de Pita O; Borradori L; Uter W; Hertl M
Clin Immunol; 2010 Mar; 134(3):320-30. PubMed ID: 20015693
[TBL] [Abstract][Full Text] [Related]
19. Involvement of T(H)1/T(H)2 cytokines in the pathogenesis of autoimmune skin disease-Pemphigus vulgaris.
Satyam A; Khandpur S; Sharma VK; Sharma A
Immunol Invest; 2009; 38(6):498-509. PubMed ID: 19811408
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3 specific T cell responses in pemphigus vulgaris patients and normals.
Hertl M; Karr RW; Amagai M; Katz SI
J Invest Dermatol; 1998 Apr; 110(4):388-92. PubMed ID: 9540980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
